Compare Neurocrine Biosciences Inc (NBIX) vs Super Micro Computer Inc (SMCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Super Micro Computer Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Super Micro Computer Inc trades at $41.86 (market cap $28.10B). The key difference: Super Micro Computer Inc is the larger of the two by market cap, and Super Micro Computer Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Super Micro Computer Inc for 19 Days on average.
| NBIX | SMCI | |
|---|---|---|
Market Cap | $14.36B | $28.10B |
Volume | 1,237,180 | 38,581,805 |
Sector | Health | Technology |
52-Week High | $185.50 | $55.04 |
52-Week Low | $123.10 | $20.53 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | $14.37B | $33.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Super Micro Computer (SMCI) trades at $42.77, down 4.85% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats and robust revenue growth to $39.1B in 2026 highlight its AI infrastructure strength. The stock is near its consensus price target of $42.33, with support at $42 and resistance at $44.
Outlook remains positive driven by AI server demand, though risks include margin pressure and a DOJ investigation. Analysts are mixed with 36% buy ratings, but the low P/E of 13.12 offers value if growth sustains. Investors should weigh execution risks against the company's strategic position in expanding AI markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →
